Best practices for Orange Book listings

21 November 2023
fda_building_big

This week's Expert View comes from Jonathan Roses, a patent attorney at Boston, USA-based law firm Wolf Greenfield. In the context of an ever-evolving regulatory landscape, Mr Roses provides insights into how to successfully navigate the complexities of the US Food and Drug Administration's all-important "Orange Book."

In 1984, Congress passed and the President signed into law the Drug Price Competition and Patent Term Restoration Act, better known as the Hatch-Waxman Act.

As part of its creation of the modern generic drug, patent term restoration, and regulatory exclusivity schemes, Hatch-Waxman created the Orange Book to enable potential sponsors of new generic drugs to assess which patents might be asserted against them if they were to receive approval for and market a proposed generic product.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical